Tarsus Pharmaceuticals Inc expected to post a loss of 94 cents a share - Earnings Preview

Tarsus Pharmaceuticals

12/11/2024 03:50

* Tarsus Pharmaceuticals Inc  TARS.OQ   TARS.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 13 for the period ending September 30 2024
    * The Irvine California-based  company is expected to report
a
2,221.6% increase in revenue to $43.438 million from $1.87
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Tarsus Pharmaceuticals
Inc is
for a loss of 94 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is 61.50​, above​ its last closing price
of $49.08. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.21       -0.92      -0.88     Beat    4.8
 Mar. 31 0001  -1.21       -1.20      -1.01     Beat    16.2
 Dec. 31 2023  -1.39       -1.36      -1.31     Beat    3.9​
 Sep. 30 2023  -1.29       -1.37      -1.28     Beat    6.3
 ​​Jun.        -1.06       -1.08      -1.17     Missed  -8.5
 30 2023                                                
 Mar. 31 2023  -0.92       -0.94      -0.88     Beat    6.9​
 Jan. 1 0001               -0.69      -0.49     Beat    29
 Sep. 30 2022  -0.88       -0.97      -0.84     Beat    13.7
 This summary was machine generated November 12 at 03:50 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)